endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Bris­tol My­ers pulls lym­phoma in­di­ca­tion for Is­to­dax af­ter con­fir­ma­to­ry tri­al falls flat

4 years ago
Pharma

Mod­er­na takes on a low-risk pact with CAR-T play­er Au­to­lus for mR­NA-based can­cer drugs

4 years ago
Deals

Ab­b­Vie, rid­ing the Aduhelm af­ter­glow, hand­picks be­ta amy­loid drug for fur­ther R&D as it bails on tau

4 years ago
R&D
Pharma

BeiGene looks to carve out more space in the US mar­ket, set­ting up BTK drug for 2nd blood can­cer nod

4 years ago
R&D
China

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

4 years ago
Deals

Bris­tol My­er­s' Op­di­vo turns the boat around in Q2 as man­u­fac­tur­ing is­sues haunt CAR-T launch

4 years ago
Pharma

Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

4 years ago
Deals
R&D

No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

4 years ago
Financing

Bay­er poach­es newest ear­ly R&D head from Roche; Glax­o­SmithK­line earns ex­pand­ed nod for Shin­grix

4 years ago
News Briefing

The clock is tick­ing for Iterum af­ter FDA hands down CRL for Pfiz­er castoff an­tibi­ot­ic

4 years ago
R&D
FDA+

Mer­ck, Ei­sai notch full ap­proval for Keytru­da-TKI in­hibitor com­bo in ad­vanced en­dome­tri­al can­cer

4 years ago
Pharma
FDA+

As­traZeneca, Alex­ion close mas­sive $39B merg­er; blue­bird bio earns EU nod for Lenti-D as big split ap­proach­es

4 years ago
News Briefing

FDA lev­els clin­i­cal hold on Ma­gen­ta's sec­ond lead drug, ask­ing for an ad­di­tion­al bioas­say be­fore it gets to hu­mans

4 years ago
R&D

Health­care ven­ture cap­i­tal has al­ready blown away 2020 records, but does it have the juice to keep grow­ing?

4 years ago
Financing

A No­var­tis castoff with a trou­bled past head­lines Chi­nese biotech's Hong Kong IPO quest

4 years ago
Financing
China

Chi­nese an­ti­body play­er chas­es Hong Kong IPO with lead Rit­ux­an chal­lenger ready for late-stage test

4 years ago
Financing
China

As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

4 years ago
China
Pharma

Re­gen­eron, al­ready an in­sti­tu­tion in NY, earns Cuo­mo's back­ing for a $1.8B ex­pan­sion at Tar­ry­town hive

4 years ago
Financing
Pharma

Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

4 years ago
R&D
Pharma

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and ...

4 years ago
Financing
Cell/Gene Tx

Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

4 years ago
Biotech Voices

EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

4 years ago
Deals
FDA+

Nkar­ta signs its name to an am­bi­tious fu­ture with man­u­fac­tur­ing hub for not one but mul­ti­ple mar­ket­ed drugs

4 years ago
Cell/Gene Tx
Manufacturing

With Eli Lil­ly's back­ing, a team of Seagen vet­er­ans with ADC chops is look­ing to crash the Chi­nese on­col­o­gy par­ty

4 years ago
Financing
China
First page Previous page 6789101112 Next page Last page
A service from the Financial Times